Compare Enveric Biosciences Inc (ENVB) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs iShares MSCI China ETF — how do they compare? Enveric Biosciences Inc trades at $1.37 (market cap $5.32M), while iShares MSCI China ETF trades at $54.17. The key difference: iShares MSCI China ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | MCHI | |
|---|---|---|
Market Cap | $5.32M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $17.40 | $66.99 |
52-Week Low | $1.28 | $50.48 |
Enterprise Value | $408.82K | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
MCHI trades at $54.10, up 1.63% with a bullish technical signal from moving averages. The stock shows strong momentum with ADX indicating a strong trend, though RSI levels suggest potential overbought conditions. Recent news highlights China's AI and manufacturing resurgence, with exports growing 19.4% year-over-year in May 2026 (Reuters, 2026-06-08).
The outlook remains cautiously optimistic given China's $295 billion AI investment plan (Bloomberg, 2026-06-09) and factory rebound. However, risks include US-China trade tensions and concerns about Chinese equities being value traps. Analyst sentiment is mixed with some maintaining sell ratings due to structural headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
